Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNFW 180 Life Sciences	$0.22 +10.1%	$0.07	$0.00 ▼ $0.62	N/A	N/A	501,334 shs	926,337 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
ONCS OncoSec Medical		$0.52	$0.18 ▼ $20.46	$1.26M	1.99	2.22 million shs	52.49 million shs
SXTPW 60 Degrees Pharmaceuticals	$0.11	$0.07	$0.01 ▼ $0.16	N/A	N/A	14,400 shs	100 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNFW 180 Life Sciences	+10.14%	-48.83%	+2,015.87%	+2,834.00%	+2,685.44%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
ONCS OncoSec Medical	0.00%	0.00%	0.00%	0.00%	0.00%
SXTPW 60 Degrees Pharmaceuticals	0.00%	+0.09%	+26.82%	+119.40%	+63.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNFW 180 Life Sciences	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A
ONCS OncoSec Medical	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	$3.42 per share	N/A
SXTPW 60 Degrees Pharmaceuticals	$641.41K	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNFW 180 Life Sciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
ONCS OncoSec Medical	-$34.18M	-$15.29	N/A	N/A	N/A	N/A	-868.29%	-160.61%	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNFW 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNFW 180 Life Sciences	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	0.59	0.59
ONCS OncoSec Medical	N/A	0.89	0.89
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNFW 180 Life Sciences	N/A
NMTR 9 Meters Biopharma	22.34%
ONCS OncoSec Medical	8.69%
SXTPW 60 Degrees Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATNFW 180 Life Sciences	N/A
NMTR 9 Meters Biopharma	2.40%
ONCS OncoSec Medical	1.32%
SXTPW 60 Degrees Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNFW 180 Life Sciences	7	N/A	N/A	Not Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
ONCS OncoSec Medical	40	4.55 million	4.49 million	Not Optionable
SXTPW 60 Degrees Pharmaceuticals	2	N/A	N/A	Not Optionable

ONCS, NMTR, ATNFW, and SXTPW Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals Initiates Phase II Clinical Trial of Tafenoquine for Chronic Babesiosis Treatment

August 19, 2025 | quiverquant.comQ

60 Degrees Pharmaceuticals Reports Q2 2025 Earnings

August 13, 2025 | tipranks.com

60 Degrees Pharmaceuticals Inc (SXTP) - Investing.com UK

July 23, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

July 19, 2025 | finance.yahoo.com

60 Degrees Pharmaceuticals Secures $5M in Recent Offering

July 18, 2025 | tipranks.com

60 Degrees Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

July 15, 2025 | quiverquant.comQ

60 Degrees Pharmaceuticals Inc (SXTP) - Investing.com

June 30, 2025 | investing.com

60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 6, 2025 | usatoday.com

60 Degrees Pharmaceuticals Introduces New 8-Count Bottle for ARAKODA® Malaria Prophylaxis

June 6, 2025 | nasdaq.com

60 Degrees introduces eight-count bottle format for ARAKODA

June 4, 2025 | msn.com

60 Degrees announces results from an insurance claims analysis on babesiosis

June 4, 2025 | finance.yahoo.com

60 Degrees Pharmaceuticals Highlights Major Discrepancies in Babesiosis Diagnosis Estimates in U.S.

April 24, 2025 | nasdaq.com

60 Degrees Pharmaceuticals signs Patient License Agreement with Yale

April 8, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals Announces 2024 Annual Results

March 28, 2025 | finance.yahoo.com

60 Degrees Pharmaceuticals Inc trading halted, news pending

February 21, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holder

February 14, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals announces stock and warrant sale

January 29, 2025 | msn.com

The Market’s Eyeing 60 Degrees Pharmaceuticals (SXTP): Will the Surge Last?

January 29, 2025 | bovnews.comB

Media Sentiment Over Time

ONCS, NMTR, ATNFW, and SXTPW Company Descriptions

180 Life Sciences NASDAQ:ATNFW

$0.22 +0.02 (+10.11%)

As of 08/22/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

OncoSec Medical NASDAQ:ONCS

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.11 0.00 (0.00%)

As of 08/22/2025

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time